303 related articles for article (PubMed ID: 29450683)
1. Common Adverse Effects of Novel Therapies for Multiple Myeloma (MM) and Their Management Strategies.
McCullough KB; Hobbs MA; Abeykoon JP; Kapoor P
Curr Hematol Malig Rep; 2018 Apr; 13(2):114-124. PubMed ID: 29450683
[TBL] [Abstract][Full Text] [Related]
2. Current strategies for treatment of relapsed/refractory multiple myeloma.
Laubach JP; Voorhees PM; Hassoun H; Jakubowiak A; Lonial S; Richardson PG
Expert Rev Hematol; 2014 Feb; 7(1):97-111. PubMed ID: 24471924
[TBL] [Abstract][Full Text] [Related]
3. Management of adverse events induced by next-generation immunomodulatory drug and proteasome inhibitors in multiple myeloma.
Salvini M; Bonello F; Boccadoro M; Larocca A
Expert Rev Anticancer Ther; 2017 Jan; 17(1):75-87. PubMed ID: 27894203
[TBL] [Abstract][Full Text] [Related]
4. Navigating the treatment landscape in multiple myeloma: which combinations to use and when?
Goldschmidt H; Ashcroft J; Szabo Z; Garderet L
Ann Hematol; 2019 Jan; 98(1):1-18. PubMed ID: 30470875
[TBL] [Abstract][Full Text] [Related]
5. Current and New Therapeutic Strategies for Relapsed and Refractory Multiple Myeloma: An Update.
Nijhof IS; van de Donk NWCJ; Zweegman S; Lokhorst HM
Drugs; 2018 Jan; 78(1):19-37. PubMed ID: 29188449
[TBL] [Abstract][Full Text] [Related]
6. Emerging therapies in multiple myeloma.
El-Amm J; Tabbara IA
Am J Clin Oncol; 2015 Jun; 38(3):315-21. PubMed ID: 23934133
[TBL] [Abstract][Full Text] [Related]
7. An update in treatment options for multiple myeloma in nontransplant eligible patients.
Broijl A; Sonneveld P
Expert Opin Pharmacother; 2015; 16(13):1945-57. PubMed ID: 26245702
[TBL] [Abstract][Full Text] [Related]
8. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.
Ashjian E; Redic K
J Oncol Pharm Pract; 2016 Apr; 22(2):289-302. PubMed ID: 25694345
[TBL] [Abstract][Full Text] [Related]
9. Safety issues and management of toxicities associated with new treatments for multiple myeloma.
Brioli A; Mügge LO; Hochhaus A; Von Lilienfeld-Toal M
Expert Rev Hematol; 2017 Mar; 10(3):193-205. PubMed ID: 28116920
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular Complications Associated with Multiple Myeloma Therapies: Incidence, Pathophysiology, and Management.
Patel VG; Cornell RF
Curr Oncol Rep; 2019 Mar; 21(4):29. PubMed ID: 30834998
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors in multiple myeloma: from bench to bedside.
Harada T; Hideshima T; Anderson KC
Int J Hematol; 2016 Sep; 104(3):300-9. PubMed ID: 27099225
[TBL] [Abstract][Full Text] [Related]
12. Emerging biological insights and novel treatment strategies in multiple myeloma.
Gentile M; Recchia AG; Mazzone C; Morabito F
Expert Opin Emerg Drugs; 2012 Sep; 17(3):407-38. PubMed ID: 22920042
[TBL] [Abstract][Full Text] [Related]
13. Optimal Management of Histone Deacetylase Inhibitor-Related Adverse Events in Patients With Multiple Myeloma: A Focus on Panobinostat.
Cavenagh JD; Popat R
Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):501-507. PubMed ID: 29804873
[TBL] [Abstract][Full Text] [Related]
14. Future agents and treatment directions in multiple myeloma.
Ocio EM; Mitsiades CS; Orlowski RZ; Anderson KC
Expert Rev Hematol; 2014 Feb; 7(1):127-41. PubMed ID: 24350987
[TBL] [Abstract][Full Text] [Related]
15. Sequential or combination therapy for multiple myeloma.
Nooka A; Lonial S
Expert Rev Hematol; 2012 Oct; 5(5):533-45. PubMed ID: 23146057
[TBL] [Abstract][Full Text] [Related]
16. How is patient care for multiple myeloma advancing?
Genadieva Stavric S; Bonello F; Bringhen S; Boccadoro M; Larocca A
Expert Rev Hematol; 2017 Jun; 10(6):551-561. PubMed ID: 28504554
[TBL] [Abstract][Full Text] [Related]
17. A question of class: Treatment options for patients with relapsed and/or refractory multiple myeloma.
Cook G; Zweegman S; Mateos MV; Suzan F; Moreau P
Crit Rev Oncol Hematol; 2018 Jan; 121():74-89. PubMed ID: 29279102
[TBL] [Abstract][Full Text] [Related]
18. Systematic review and meta-analysis of the efficacy and safety of novel monoclonal antibodies for treatment of relapsed/refractory multiple myeloma.
Zhang T; Wang S; Lin T; Xie J; Zhao L; Liang Z; Li Y; Jiang J
Oncotarget; 2017 May; 8(20):34001-34017. PubMed ID: 28454113
[TBL] [Abstract][Full Text] [Related]
19. Resistance to proteasome inhibitors and other targeted therapies in myeloma.
Wallington-Beddoe CT; Sobieraj-Teague M; Kuss BJ; Pitson SM
Br J Haematol; 2018 Jul; 182(1):11-28. PubMed ID: 29676460
[TBL] [Abstract][Full Text] [Related]
20. New Agents in Multiple Myeloma: An Examination of Safety Profiles.
Bringhen S; De Wit E; Dimopoulos MA
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17(7):391-407.e5. PubMed ID: 28601492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
